JP2020502218A - 骨形成不全症の処置における抗スクレロスチン抗体の使用 - Google Patents

骨形成不全症の処置における抗スクレロスチン抗体の使用 Download PDF

Info

Publication number
JP2020502218A
JP2020502218A JP2019533573A JP2019533573A JP2020502218A JP 2020502218 A JP2020502218 A JP 2020502218A JP 2019533573 A JP2019533573 A JP 2019533573A JP 2019533573 A JP2019533573 A JP 2019533573A JP 2020502218 A JP2020502218 A JP 2020502218A
Authority
JP
Japan
Prior art keywords
amino acid
patient
acid sequence
sclerostin antibody
sclerostin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019533573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502218A5 (cg-RX-API-DMAC7.html
Inventor
ユンカー，ウヴェ
クナイセル，ミカエラ
ケント ハル，アントニー
ケント ハル，アントニー
ジョイ ユディ，レナ
ジョイ ユディ，レナ
マニング リグス，マシュー
マニング リグス，マシュー
Original Assignee
メレオ バイオファーマ ３ リミテッド
メレオ バイオファーマ ３ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メレオ バイオファーマ ３ リミテッド, メレオ バイオファーマ ３ リミテッド filed Critical メレオ バイオファーマ ３ リミテッド
Publication of JP2020502218A publication Critical patent/JP2020502218A/ja
Publication of JP2020502218A5 publication Critical patent/JP2020502218A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2019533573A 2016-12-21 2017-12-21 骨形成不全症の処置における抗スクレロスチン抗体の使用 Pending JP2020502218A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437358P 2016-12-21 2016-12-21
US62/437,358 2016-12-21
PCT/GB2017/053849 WO2018115879A1 (en) 2016-12-21 2017-12-21 Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Publications (2)

Publication Number Publication Date
JP2020502218A true JP2020502218A (ja) 2020-01-23
JP2020502218A5 JP2020502218A5 (cg-RX-API-DMAC7.html) 2021-02-04

Family

ID=60888539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019533573A Pending JP2020502218A (ja) 2016-12-21 2017-12-21 骨形成不全症の処置における抗スクレロスチン抗体の使用

Country Status (3)

Country Link
US (3) US10961305B2 (cg-RX-API-DMAC7.html)
JP (1) JP2020502218A (cg-RX-API-DMAC7.html)
WO (1) WO2018115879A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220051269A (ko) * 2016-12-21 2022-04-26 메레오 바이오파마 3 리미티드 불완전 골형성증 치료에서의 항-스클레로스틴 항체의 용도
JP2020502218A (ja) 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用
EP4408884A4 (en) * 2021-09-30 2025-04-23 Mereo Biopharma 3 Limited Method for using anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
WO2025036493A1 (en) * 2023-08-17 2025-02-20 Sinomab Bioscience Limited Antibodies targeting rankl and sclerostin and uses thereof

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
SE8804164A0 (sv) 1988-11-17 1990-05-18 Per Prisell Farmaceutisk beredning
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5177197A (en) 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5229495A (en) 1991-06-18 1993-07-20 Ludwig Institute For Cancer Research Substantially pure receptor like TGF-β 1 binding molecules and uses thereof
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DK0662146T3 (da) 1992-09-03 2000-11-13 Univ California Dorsalvævpåvirkende faktor og præparat
US5453492A (en) 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
JPH09512910A (ja) 1994-05-04 1997-12-22 マウント・サイナイ・ホスピタル・コーポレイション ＴＧＦ−βスーパーファミリーのサイトカインの変調因子およびそのアッセイ方法
US5616561A (en) 1995-03-31 1997-04-01 Regents Of The University Of California TGF-β antagonists as mitigators of radiation-induced tissue damage
NZ500577A (en) 1997-04-29 2001-02-23 Regeneron Pharma Human cerberus protein that regulates cell function, induce neural development or antagonise bone morphogenic proteins
CA2292899A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
US5935852A (en) 1997-07-03 1999-08-10 Genetics Institute, Inc. DNA molecules encoding mammalian cerberus-like proteins
AU4409899A (en) 1998-05-28 1999-12-13 Board Of Trustees Of The University Of Arkansas, The Noggin and antagonists of bone morphogenetic proteins to suppress pathologic bone resorption
WO2000022909A2 (en) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
CN101469329B (zh) 1998-11-27 2012-10-24 达尔文发现有限公司 增加骨矿化的组合物和方法
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
WO2000055193A2 (en) 1999-03-12 2000-09-21 Regeneron Pharmaceuticals, Inc. Human dan/cerberus related protein 6 (dcr6)
US7358056B1 (en) 1999-08-30 2008-04-15 Signal Pharmaceuticals Methods for modulating signal transduction mediated by TGF-β and related proteins
WO2001047944A2 (en) 1999-12-28 2001-07-05 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
AU2001236519A1 (en) 2000-01-24 2001-07-31 Millennium Pharmaceuitcals, Inc. Identification, assessment, prevention, and therapy of prostate cancer
AU2001229508A1 (en) 2000-01-31 2001-08-07 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001236589A1 (en) 2000-02-04 2001-08-14 Aeomica, Inc. Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes
US20040087016A1 (en) 2000-05-12 2004-05-06 University Of Utah Research Foundation Compositions and methods for cell dedifferentiation and tissue regeneration
AU6459801A (en) 2000-05-12 2001-11-26 Mark T Keating Compositions and methods for cell dedifferentiation and tissue regeneration
US20020106650A1 (en) 2000-06-01 2002-08-08 Paszty Christopher J. Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
AU2001272482A1 (en) 2000-06-19 2002-01-02 F.Hoffmann-La Roche Ag Osteolevin gene polymorphisms
EP1370287A2 (en) 2000-12-01 2003-12-17 Wyeth Method and composition for modulating bone growth
WO2002054940A2 (en) 2001-01-12 2002-07-18 University Of Medicine & Dentistry Of New Jersey Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
JP2005511593A (ja) 2001-11-08 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド 骨粗鬆症を治療するための組成物及び方法
EP1504099A4 (en) 2001-12-10 2006-05-10 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
GB0130738D0 (en) 2001-12-21 2002-02-06 Serono Internat S A Protein
GB2385052A (en) 2002-02-05 2003-08-13 Leuven K U Res & Dev Treatment of spondyloarthropathies
US20030186915A1 (en) 2002-02-11 2003-10-02 Yang Pan Regulatory polynucleotides and uses thereof
JP2005253301A (ja) 2002-02-20 2005-09-22 Taisho Pharmaceut Co Ltd 骨形成蛋白結合領域を有する蛋白質及びそれをコードする遺伝子
EP1575481A4 (en) 2002-03-01 2010-01-06 Celltech R & D Inc PROCESS FOR INCREASING OR REDUCING THE BONE DENSITY
US7799523B2 (en) 2002-04-03 2010-09-21 Celltech R & D, Inc. Association of polymorphisms in the SOST gene region with bone mineral density
CA2486113A1 (en) 2002-05-17 2003-12-04 Wyeth Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
AU2003276430A1 (en) 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
WO2004041277A1 (en) 2002-11-01 2004-05-21 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
US20060276385A1 (en) 2003-01-13 2006-12-07 Hanjoong Jo Anti-inflammatory agents and methods of their use
WO2004082608A2 (en) 2003-03-14 2004-09-30 Celltech R & D, Inc. Ligands for tgf-beta binding proteins and uses thereof
AU2004238238C1 (en) 2003-05-07 2010-01-14 Merck Sharp & Dohme Corp. Androgen receptor modulators and methods of use thereof
CN1835974A (zh) 2003-06-16 2006-09-20 细胞技术研究与发展公司 对硬化素特异的抗体和用于增加骨矿化的方法
WO2005023311A2 (en) 2003-09-11 2005-03-17 Association Francaise Retinitis Pigmentosa (Afrp) Novel targets for the treatment of retina diseases
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
EP1670425A4 (en) 2003-10-07 2008-04-16 Quark Pharmaceuticals Inc BONE MORPHOGENETIC PROTEIN (BMP) 2A AND ITS APPLICATIONS
CA2566746A1 (en) 2004-05-14 2005-12-01 Baylor College Of Medicine Beta adrenergic drug conjugated to bone targeting moiety for modulating bone mass
JP2008509087A (ja) 2004-05-27 2008-03-27 アクセルロン ファーマ インコーポレーテッド Ｔｇｆ抑制解除因子およびそれに関連する使用方法
EP1863340A2 (en) 2005-03-11 2007-12-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US20060293667A1 (en) 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
WO2006135734A2 (en) 2005-06-10 2006-12-21 The Regents Of The University Of California Compositions and methods for altering bone density and bone patterning
EP1981910B1 (en) 2006-01-13 2013-06-26 A Chan Holding B.V. Method for identifying inhibitor of the glypican-sclerostin interaction
EP2097450A2 (en) 2006-11-10 2009-09-09 Amgen Inc. Antibody-based diagnostics and therapeutics
EP2094731A2 (en) 2006-11-10 2009-09-02 UCB Pharma S.A. Anti human sclerostin antibodies
PL3345607T3 (pl) 2006-12-29 2023-01-09 Ossifi-Mab Llc Sposoby modyfikowania wzrostu kości poprzez podanie antagonisty lub agonisty sost lub wise
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
US20110044978A1 (en) 2007-12-14 2011-02-24 Amgen Inc. Method for treating bone fracture
WO2010100200A2 (en) * 2009-03-05 2010-09-10 Novartis Ag Lyophilised antibody formulation
WO2010115932A1 (en) * 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
US9617323B2 (en) 2010-06-07 2017-04-11 Joshua Rabbani Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor
ES2863626T3 (es) 2010-10-27 2021-10-11 Amgen Inc Anticuerpos DKK1 y métodos de uso
EP2681242B1 (en) 2011-03-01 2018-01-24 Amgen Inc. Sclerostin and dkk-1 bispecific binding agents
MX338078B (es) 2011-03-25 2016-04-01 Amgen Inc Cristales de anticuerpos anti-esclerostina y formulaciones de los mismos.
SMT202000494T1 (it) 2011-04-19 2020-11-10 Amgen Inc Metodo per il trattamento dell'osteoporosi
LT2739311T (lt) 2011-08-04 2018-06-11 Amgen Inc. Kaulų tarpų defektų gydymo būdas
WO2013101451A1 (en) 2011-12-28 2013-07-04 Amgen Inc. Method of treating alvelor bone loss through the use of anti-sclerostin antibodies
CN104619342A (zh) 2012-07-05 2015-05-13 Ucb医药有限公司 骨疾病的治疗
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
WO2017027861A1 (en) 2015-08-13 2017-02-16 Amgen Inc. Charged depth filtration of antigen-binding proteins
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
KR20190037261A (ko) 2016-08-08 2019-04-05 암젠 인크 항-스클레로스틴 항체를 사용한 결합 조직 부착 개선 방법
JP2020502218A (ja) 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用
KR20220051269A (ko) 2016-12-21 2022-04-26 메레오 바이오파마 3 리미티드 불완전 골형성증 치료에서의 항-스클레로스틴 항체의 용도
EP3596225A1 (en) 2017-03-14 2020-01-22 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
KR20200034748A (ko) 2017-07-27 2020-03-31 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Sost 항체 약학적 조성물 및 그의 용도
CN111954719B (zh) 2018-03-26 2025-07-18 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
IL316596A (en) 2018-03-30 2024-12-01 Amgen Inc C-terminal antibody variants
JP7425041B2 (ja) 2018-08-10 2024-01-30 アムジエン・インコーポレーテツド 抗体医薬製剤を作製する方法

Also Published As

Publication number Publication date
WO2018115879A1 (en) 2018-06-28
US10961305B2 (en) 2021-03-30
US20190330322A1 (en) 2019-10-31
US20250122273A1 (en) 2025-04-17
US12173058B2 (en) 2024-12-24
US20210253687A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
US20230365669A1 (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
JP6353500B2 (ja) Ｄｋｋ１抗体およびその使用方法
JP6845012B2 (ja) 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用
US20250122273A1 (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
KR101620771B1 (ko) Ｉｌ―17 길항제를 사용하는 건선의 치료 방법
KR20170045240A (ko) 건선성 관절염 환자에서 구조적 손상의 진행을 억제하기 위한 il-17 길항제의 용도
TW202323278A (zh) 使用抗硬骨抑素抗體治療成骨不全之方法
HK40058082A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
HK40007021A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
HK40007021B (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
TW202346345A (zh) 面肩胛肱肌失養症（ｆｓｈｄ）之新治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220510